On the basis of established, genetic and non-genetic risk factors, we build quantitative risk models for the identification of individuals who have an increased risk of developing cancer compared to others, and who may gain increased benefit from targeted prevention measures such as regular cancer screening.
A further focus is exploring new routes for prevention and early diagnosis of cancer, as well as quality control of introduced measures. Due to their population-related approach, statistical methods and their further development are of particularly high relevance in epidemiology.
A major part of our research takes place within the setting of large-scale prospective cohort studies, such as the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Scandinavian Consortium of Maternity Cohorts. Besides these prospective studies in the general population, our division conducts studies within large cohorts of cancer patients.
FUTURE OUTLOOK
Studies within our various prospective cohorts are increasingly making use of modern, high-throughput “omics” technologies (metabolomics, genomics, epigenomics, next-generation sequencing) for the identification of risk factors and predictors for cancer and markers for early detection.
For future studies, our division has a central role in the development and set-up of the “NAKO” – a new, large-scale prospective cohort study in Germany.
